Listed by the USPTO as PURDY, KYLE A
Tech Center 1600 • Art Units: 1611
This examiner grants 41% of resolved cases
PURDY, KYLE A is assigned to tech center 1600 and art unit 1611. His profile includes 1004 resolved cases, a 40.8% allowance rate, a 35.8% interview lift, and a median of 1519 days to allowance.
The listed companies are Textile-Based Delivery Inc., University of Florida Research Foundation Inc., and The Brigham and Women's Hospital Inc. Listed firms include NEO IP, CANTOR COLBURN LLP - UPL LIMITED, and Abel Schillinger, LLP. The allowance rate is below half, while the positive interview lift supports preparing interviews as part of a broader strategy for addressing examination issues.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630843 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18272024 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18667002 | SKIN CARE SERUM COMPOSITION WITH NATURAL POLYMERS | Final Rejection | The Procter & Gamble Company |
| 18821462 | POLYANION COATED LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18703637 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Ohio State Innovation Foundation |
| 18679898 | PURIFIED EXOSOME PRODUCTS, METHOD OF MAKING, AND METHODS OF USING | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18700612 | PLANT DISEASE RESISTANCE INDUCING METHOD, PLANT DISEASE RESISTANCE INDUCING DEVICE, AND PLANT DISEASE RESISTANCE INDUCING AGENT | Final Rejection | TOHOKU UNIVERSITY |
| 18953835 | ORAL PRODUCTS, THREE-DIMENSIONAL PRINTERS USED FOR FORMING ORAL PRODUCTS, AND THREE-DIMENSIONAL PRINTING METHODS FOR FORMING ORAL PRODUCTS | Non-Final OA | Altria Client Services LLC |
| 17422859 | ANTIBACTERIAL COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 18706889 | METHODS AND SYSTEMS FOR POINT-OF-CARE SYNTHESIS AND ADMINISTRATION OF PARTICLE-BASED THERAPEUTICS | Final Rejection | Verily Life Sciences LLC |
| 18256655 | EXTRACT OF AT LEAST ONE PLANT OF THE CROCUS SATIVUS SPECIES COMPRISING A HIGH CONTENT OF CROCINS AND A LOW CONTENT OF SAFRANAL, AND COSMETIC USE THEREOF AS ANTIOXIDANT | Final Rejection | L'OREAL |
| 18437576 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | Non-Final OA | Mitsubishi Chemical Corporation |
| 17767783 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS | Final Rejection | University of Maryland, Baltimore |
| 18867060 | CONCENTRATED CONDITIONING COMPOSITIONS | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 18723765 | LIQUID COMPOSITION HAVING ENHANCED ANTIMICROBIAL ACTIVITY | Non-Final OA | Conopco Inc., d/b/a UNILEVER |
| 17723155 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | Non-Final OA | INVENTAGE LAB INC. |
| 15551596 | COSMETIC PRODUCT COMPRISING A METAL CAN, AND THE CONTENTS OF SAME | Final Rejection | BEIERSDORF AG |
| 19104621 | COMPOSITION OF LIPID NANOPARTICLES | Non-Final OA | SUZHOU ABOGEN BIOSCIENCES CO., LTD. |
| 19001161 | COSMETIC COMPOSITIONS COMPRISING A CYCLODEXTRIN HAVING A PARTICLE SIZE DISTRIBUTION | Non-Final OA | ROQUETTE FRERES |
| 18832510 | A Composition Against Osmotic Stress | Non-Final OA | ELC Management LLC |
| 18877427 | HERBICIDAL COMBINATIONS AND A METHOD FOR CONTROLLING UNDESIRED VEGETATION | Non-Final OA | UPL Europe Ltd. |
| 18252656 | Base Sheet with Surface Fiber Structure | Final Rejection | Alejandra ZAPATA ARANGO |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy40.8% of resolved applications examined by Kyle A Purdy were allowed (1,004 resolved cases), compared with 35.4% across Art Unit 1611 over the last five years.
This examiner's interview lift is +35.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kyle A Purdy took 1,519 days on average from filing to allowance.
Kyle A Purdy examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).